Nevanac (nepafenac) / Novartis, Harrow Health - LARVOL DELTA

Transient maculopathy after intracameral injection of cefuroxime (PubMed, Ophthalmologie) - "These findings completely resolved within 6 days of treatment with prednisolone acetate and nepafenac eye drops, resulting in full visual recovery.Intracameral administration of antibiotics, in Europe as cefuroxime 1 mg/0.1 ml, is recommended for endophthalmitis prophylaxis at the end of cataract surgery. Patients who have undergone pars plana or anterior vitrectomy apparently have an inherently higher risk of developing maculopathy. Transient cefuroxime maculopathy usually has a benign, self-limiting course. Cataract surgeons should be aware of this condition and avoid overdosing that otherwise safe and effective drug."

Journal • Cataract • Macular Degeneration • Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders

Effect of Topical NSAIDs (Diclofenac 0.1%, Nepafenac 0.1%, Nepafenac 0.3%) on Pain Management During Intravitreal Injections: A Prospective, Non-Randomized, Case-Control Trial (ChiCTR) - P=N/A | N=400 | Not yet recruiting | Sponsor: Fauji Foundation Hospital Rawalpindi, Pakistan; Fauji Foundation Hospital

New trial • Pain

The effects of topical nepafenac on pupillary dynamics in early postoperative period following uneventful cataract surgery: a prospective randomized study. (PubMed, Int Ophthalmol) - "Adjunctive topical Nepafenac 0.1% use might attenuate early postoperative scotopic and mesopic pupil constriction following an uneventful cataract surgery. Although the effect appears most pronounced during the first postoperative week, this short-term benefit may be clinically relevant, particularly for patients with premium intraocular lens or those who rely heavily on low-light vision."

Clinical • Journal • Cataract • Inflammation • Ophthalmology

Analgesic efficacy of 7 different topical NSAIDs in panretinal photocoagulation-associated pain. (PubMed, BMC Ophthalmol) - "Bromfenac and indomethacin demonstrate consistent analgesic efficacy in nearly all patients with panretinal photocoagulation-related pain, while nepafenac 0.3% and diclofenac are effective in a majority of cases. However, heightened panretinal photocoagulation-related pain in females, patients aged ≤ 60 years and those with proliferative diabetic retinopathy may necessitate careful consideration in these populations."

Journal • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Pain • Retinal Disorders

Efficacy of Topical Non-Selective and COX-2 Selective NSAIDs in Accelerating Resolution of Acute Central Serous Chorioretinopathy: A Retrospective Analysis. (PubMed, Clin Ophthalmol) - "Patients received either topical ketorolac (n = 26, nonselective NSAID, four times daily) or observation alone (n = 63). Historical data (2007-2013) (n = 111) comparing COX-2 selective NSAIDs (bromfenac or nepafenac, n = 38) with observation (n = 73) were analyzed for comparison...The earlier recovery of normal vision and anatomical resolution may benefit patients clinically by reducing morbidity associated with prolonged retinal detachment. Prospective studies are warranted to confirm these findings and refine treatment protocols for acute CSCR."

Journal • Retrospective data • Ocular Inflammation • Ophthalmology • Retinal Disorders

Development of 3D printed biodegradable polymer-based drug delivery implants for post cataract surgery treatment. (PubMed, J Biomater Sci Polym Ed) - "The implant was designed to be placed into the capsular bag of the eye during the surgery and employs Poly(lactic-co-glycolic acid) (PLGA) as a drug carrier, delivering a combination of drugs such as Dexamethasone (DEX), Moxifloxacin (MOX), and Nepafenac (NEPA) directly into the eye...This approach demonstrates the feasibility of combining cataract surgery with post-operative drug delivery in a single procedure. The implants provided sustained drug release profiles consistent with clinical dosing regimens and were well substantiated in in vivo rabbit model, supporting their potential to improve patient compliance and recovery in future therapeutic applications."

Journal • Cataract • Ophthalmology

BND: Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery (clinicaltrials.gov) - P=N/A | N=150 | Recruiting | Sponsor: Nemocnice Kolín

New trial • Cataract • Macular Edema • Ophthalmology

Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy (clinicaltrials.gov) - P4 | N=61 | Completed | Sponsor: Indonesia University

Biomarker • New P4 trial • Retinal Disorders

Comparative efficacy of non-steroidal anti-inflammatory drugs in preventing postoperative macular edema following cataract surgery: a systematic review and Network Meta-analysis. (PubMed, Int J Ophthalmol) - "This Network Meta-analysis suggests that nepafenac is the most effective NSAID for preventing PME following cataract surgery. Given the substantial heterogeneity observed, further high-quality RCTs are required to confirm these findings and explore the sources of variability. Clinicians should consider these results when selecting NSAIDs for PME prophylaxis in cataract surgery patients."

Journal • Retrospective data • Cataract • Macular Edema • Ophthalmology

A Retrospective Data Analysis of Patients Treated with Difluprednate and Bromfenac for Cystoid Macular Edema After Uveitis or Cataract Surgery. (PubMed, Clin Ophthalmol) - "The ANOVA test revealed significant differences among treatment groups (F-value: 6.455, P-value: <0.00001), and Tukey's HSD test showed that difluprednate and bromfenac significantly outperformed other medications in treating cystoid macular edema (CME) by reducing resolution times by 5.40 months compared to ketorolac alone (P = 0.0011), 4.76 months compared to ketorolac and prednisolone acetate (P = 0.0001), 5.42 months compared to loteprednol and nepafenac (P < 0.0001), 5.40 months compared to dexamethasone and nepafenac (P < 0.0001), and 4.47 months compared to no treatment (P = 0.0240). Difluprednate and bromfenac also had no cases of CME recurrence. Difluprednate and bromfenac proved to be the most effective treatment regimen for cystoid macular edema (CME), resolving the condition in the shortest amount of time and requiring less frequent dosing."

Journal • Retrospective data • Cataract • Macular Edema • Ocular Inflammation • Ophthalmology • Uveitis

Synergic Effect of Methyl-β-Cyclodextrin and Hydrophilic Polymers on Nepafenac Solubilization: Development of a 0.3% Ophthalmic Solution. (PubMed, Molecules) - "Compared to complexes of nepafenac with other cyclodextrins, only 5% RAMEB was sufficient to solubilize 0.3% (w/v) nepafenac, enabling for the first time the development of an ophthalmic solution that proved chemically and physically stable for 12 months at 25 °C. The formulated solutions of nepafenac were tested for cytotoxicity on human corneal epithelial cells (HCE-2) and the results suggest their potential as a valuable and safe alternative to the commercially available 0.3% (w/v) suspension of the drug."

Journal • Ocular Inflammation • Ophthalmology

Efficacy of preoperative 0.1% topical nepafenac in the prevention of cystoid macular edema after cataract surgery in diabetic patients. (PubMed, Pak J Pharm Sci) - "The nepafenac group showed a significant decrease in central macular thickness, with overall efficacy of 93.8% compared to the control group. A statistically significant difference in central macular thickness was observed between diabetic patients who received nepafenac pre- and postoperatively and those who did not."

Journal • Cataract • Diabetes • Macular Edema • Metabolic Disorders • Ophthalmology

A Case of Persistent Bilateral Irvine-Gass Syndrome Following Uneventful Cataract Surgery in a Healthy Individual. (PubMed, Cureus) - "Initial treatment with topical nepafenac 0.1% three times daily was prescribed for three months, but Irvine-Gass Syndrome persisted; hence, bilateral orbital floor triamcinolone (OFTA) of 40 mg/1 ml injection was given...Following the dexamethasone implant, the bilateral macular edema resolved and was maintained throughout 120 days. This case illustrates the stepwise treatment approach in this patient without the presence of a definitive management guideline."

Journal • Cataract • Diabetic Retinopathy • Macular Edema • Ophthalmology • Retinal Disorders

Efficacy of combined topical nepafenac 0.3% with suprachoroidal injection of triamcinolone acetonide using a modified custom needle in pseudopkakic cystoid macular edema. (PubMed, BMC Ophthalmol) - P1 | "Combined SCTA using this modified custom needle with topical nepafenac 0.3% resulted in better anatomical and functional results in PCME patients compared to topical nepafenac 0.3% alone. The study was prospectively registered with clinical trial.gov ID (NCT04690608) in 27-12-2020."

Clinical • Journal • Macular Edema • Ophthalmology

Influence of combined eplerenone, aflibercept and nepafenac therapy on central serous chorioretinopathy. (PubMed, Int J Ophthalmol) - "Using topical nepafenac in combination with both systemic eplerenone, and intravitreal aflibercept may provide better results in the treatment of CSCR."

Journal • Retinal Disorders

The added effect of preoperative nepafenac on pain and discomfort following alcohol-assisted photorefractive keratectomy. (PubMed, Ther Adv Ophthalmol) - "Study Population: 205 PRK patients grouped randomly into five according to pain-management protocols: (1) paracetamol/ibuprofen (Parac-Ibupr group, n = 39), (2) high-dose oxycodone/naloxone only (Oxy-only group, n = 45), (3) oxycodone/naloxone and postoperative 0.1%-nepafenac (Oxy-Nep group, n = 36), (4) oxycodone/naloxone and preoperative and postoperative 0.1%-nepafenac (Nep-Oxy-Nep group, n = 42), and (5) preoperative and postoperative 0.1%-nepafenac only (Nep-only group, n = 43). Adding preoperative nepafenac significantly reduced pain and photophobia with complete epithelial healing. Addition of oral opiates to nepafenac treatment had little analgetic benefit."

Journal • Addiction (Opioid and Alcohol) • Pain

Severe ocular and systemic complications of gram-negative bacteremia: a case of endophthalmitis leading to anophthalmos (SOE 2025) - "Initial treatment included topical Levofloxacin and Nepafenac 3 times daily...Visual prognosis in endophthalmitis depends on pathogen virulence, immune status, and timely intervention. Gram-negative infections, particularly P.aeruginosa, often lead to poor outcomes, with factors such as delayed treatment, reduced VA, and immune compromise contributing to prognosis frequently culminating in evisceration."

Clinical • Gram negative • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders

Comparison of topical nepafenac 0.1% and 0.3% on aqueous flare and macular thickness in patients with pseudoexfoliation following cataract surgery. (PubMed, Indian J Ophthalmol) - "Nepafenac 0.3% used in routine cataract surgery in patients with PEX was shown to be at least as effective as nepafenac 0.1% in terms of aqueous flare and CMT. Aqueous flare values were more favorable with nepafenac 0.3% during the first week. In addition, the convenience of once-daily dosing may offer further advantages."

Journal • Cataract • Ophthalmology

Automated Direct Selective Laser Trabeculoplasty in Primary Angle Closure Disease (ARVO 2025) - "All patients were prescribed nepafenac drops for a week after laser...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Glaucoma • Ophthalmology

Enhanced Ocular Bioavailability of a New Methyl-β-Cyclodextrin Nepafenac Eye drop solution. (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Ocular Inflammation • Ophthalmology

Prophylactic topical nepafenac in preventing postoperative macular edema. (PubMed, Oman J Ophthalmol) - No abstract available

Journal • Macular Edema • Ophthalmology

Fingolimod-Associated Central Serous Retinopathy Presenting Eight Years after Treatment Initiation: a Case Report. (PubMed, Maedica (Bucur)) - "Given the necessity to continue fingolimod treatment, the patient commenced topical nonsteroidal anti-inflammatory (nepafenac) medication for the retinal condition...The patient's condition remained clinically stable without recurrence of fluid during a three-month follow-up period. Our case provides insight into the fingolimod associated retinal findings manifesting as CSR changes, indicating that ocular complications may occur even in the long-term, while discontinuation of treatment may lead to reversal of structural findings and maintain functional outcomes."

Journal • CNS Disorders • Multiple Sclerosis • Ophthalmology • Retinal Disorders

Nepafenac role in macular swelling prevention and in visual outcome after cataract surgery - a systematic review and meta-analysis. (PubMed, Eur J Ophthalmol) - "Topical Nepafenac in addition to topical steroid is superior to the common regimen of topical steroid alone perioperatively in the prevention of macular swelling."

Journal • Retrospective data • Review • Cataract • Macular Edema • Ophthalmology

Development of Innovative Electrospun Nepafenac-Loaded Nanofibers-based Ophthalmic Inserts. (PubMed, Int J Pharm) - "The developed nanofiber webs could be a promising candidate for nepafenac-loaded ophthalmic inserts. Chemical compounds studied in this article Nepafenac (PubChem CID151075); Polyvinyl alcohol (PubChem CID 11199); Poloxamer 407 (PubChem CID 24751); Chloroform (PubChem CID 6212); Methanol (PubChem CID 887); L-α-phosphatidylcholine (PubChem CID 10425706); Ethylenediaminetetraacetic acid (PubChem CID 6049)."

Journal • Ophthalmology

Postoperative Pain Comparison Between Alcohol-Assisted and Transepithelial Photorefractive Keratectomy Using Nepafenac Treatment: A Novel Study. (PubMed, Ophthalmol Ther) - "The study found that patients who underwent the transepithelial-PRK procedure had significantly lower pain levels compared with those who underwent aa-PRK after being treated with nepafenac per protocol. However, there was no significant difference between the two groups in terms of stinging, tearing, light sensation, and stress levels."

Journal • Pain